中国P站

Transplant-associated malignancies; Post-transplant cancer; Immunosuppression; Oncogenesis; Epstein-Barr virus; Skin cancer; Post-transplant lymphoproliferative disorder (PTLD); Cancer screening; Graft survival; Cancer surveillance; Immunosuppressive agents; Viral oncogenesis; Risk stratification; mTOR inhibitors; Early detection; Cancer prevention; Immune surveillance; Personalized oncology; Transplant oncology; Long-term outcomes.

Introduction

While solid organ transplantation has significantly improved the lives of patients with end-stage organ disease, it also introduces long-term risks that challenge patient and graft survival. Among the most serious of these complications are transplant-associated malignancies (TAMs), a broad category of cancers that develop at a higher frequency in transplant recipients compared to the general population. This increased risk is largely attributed to the long-term use of immunosuppressive therapy, which impairs the body’s natural immune surveillance mechanisms, allowing oncogenic viruses and transformed cells to proliferate unchecked. As survival rates improve and more recipients live longer after transplantation, the burden of malignancy continues to grow. Understanding the pathogenesis, improving screening strategies, and optimizing treatment options for TAMs are essential steps in mitigating their impact on transplant outcomes [1-5].

Description

Transplant-associated malignancies encompass a wide variety of cancers, with non-melanoma skin cancers (NMSC), lymphomas, and virus-associated malignancies being the most prevalent. Among these, post-transplant lymphoproliferative disorder (PTLD) is one of the most serious and frequently encountered malignancies, often associated with Epstein-Barr virus (EBV) infection. PTLD arises from unchecked B-cell proliferation due to diminished T-cell control and is most common in the first few years following transplantation. Other malignancies, such as Kaposi sarcoma, anogenital cancers, and hepatocellular carcinoma, also occur with increased incidence due to impaired immune function and oncogenic viral coinfections, such as human papillomavirus (HPV) and hepatitis B and C viruses (HBV, HCV).

Immunosuppressive agents contribute variably to cancer risk. Calcineurin inhibitors (CNIs) like cyclosporine and tacrolimus have been shown to promote oncogenesis through both direct cellular effects and suppression of anti-tumor immunity. On the other hand, mTOR inhibitors (e.g., sirolimus, everolimus) have demonstrated antineoplastic properties and may be preferable in patients at high oncologic risk. Other risk factors include cumulative immunosuppressive exposure, prior cancer history, recipient age, sun exposure, and geographic location. Some malignancies also appear to be donor-derived, emphasizing the importance of both recipient and donor screening [6-10].

Discussion

Early screening and surveillance are pivotal to reducing the morbidity and mortality associated with TAMs. Guidelines recommend regular dermatologic examinations to monitor for skin cancers, the most common malignancies post-transplant, especially in fair-skinned individuals. Routine imaging, pap smears, colonoscopy, and prostate-specific antigen (PSA) testing should also be tailored based on individual risk factors and transplant type. For PTLD, EBV viral load monitoring is particularly valuable in high-risk patients, especially pediatric recipients or those who were EBV-seronegative at the time of transplant.

Despite these measures, screening remains inconsistently implemented across centers, often due to limited resources, lack of standardized protocols, or poor patient adherence. Moreover, many cancers in transplant recipients present at advanced stages due to subtle symptoms and delayed detection. Therefore, risk stratification models and personalized screening schedules are being developed, incorporating factors such as immune profile, viral status, and pharmacogenomics. Biomarkers and circulating tumor DNA (ctDNA) are also emerging as promising tools for early detection and real-time monitoring of malignancy in this population.

Treatment of TAMs is complicated by the need to balance cancer control with preservation of graft function. Reducing or modifying immunosuppression is often the first step, especially in cases like PTLD, where immune reconstitution can induce tumor regression. Switching from CNIs to mTOR inhibitors has shown benefit in select patients, both for preventing and treating certain cancers. However, immunosuppression reduction carries the risk of acute rejection, particularly in the early post-transplant period or in high-risk grafts. Collaboration between oncologists and transplant specialists is therefore crucial to tailor therapy.

Standard cancer treatments—surgery, chemotherapy, radiation—remain central to TAM management, but may require adjustment in dose or intensity due to immunosuppression-related comorbidities. Emerging targeted therapies and immune checkpoint inhibitors, while promising, must be used cautiously, as they may trigger immune reactivation and graft rejection. Nevertheless, ongoing research is exploring ways to harness immunotherapy safely in transplant recipients, such as by using low-dose regimens, selective pathway inhibitors, or adoptive T-cell therapies with modified specificity.

Conclusion

Transplant-associated malignancies represent a growing challenge in the care of long-term transplant recipients, necessitating a multifaceted approach that spans prevention, early detection, and individualized treatment. As the field of transplantation continues to evolve, so must the strategies to mitigate the oncologic risks introduced by chronic immunosuppression. Through the development of personalized screening programs, oncology-transplant collaboration, and innovative therapeutics, there is an opportunity to improve both cancer outcomes and graft survival. Ultimately, precision medicine approaches that integrate immunologic, virologic, and oncologic data hold the key to managing TAMs more effectively and ensuring that the life-saving benefits of transplantation are not compromised by long-term malignancy risk.

References

1. Delgado JF, Reyne AG, de Dios S, López-Medrano F, Jurado A, et al. (2015) . J Heart Lung Transplant 3:1112-1119.

   , ,

2. Raffa GM, Di Gesaro G, Sciacca S, Tuzzolino F, Turrisi M, et al. (2016) . Int J Cardiol 219: 358-361.

   , ,

3. Zieli艅ska K, Kukulski L, Wróbel M, Przyby艂owski P, Rokicka D, et al. (2022) Ann Transplant 27: 933420.

   , ,

4. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, et al. J Heart Lung Transplant 33: 241-51.

   , ,

5. Vanderlaan RD, Manlhiot C, Edwards LB, Conway J, McCrindle BW, et al. (2015) . Pediatr Transplant 19: 896-905.

   , ,

6. Kitamura S (2012) . Gen Thorac Cardiovasc Surg 60: 639-644.

   , ,

7. Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, et al. (2017) . J Heart Lung Transplant 36: 407-417.

   , ,

8. Saczkowski R, Dacey C, Bernier PL (2010) . Interact Cardiovasc Thorac Surg 10: 1026-1033.

   , ,

9. Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, et al. (2014) . J Thorac Cardiovasc Surg 147: 462-468.

   , ,

10. Sivathasan C, Lim CP, Kerk KL, Sim DK, Mehra MR, et al. (2017) . J Heart Lung Transplant 36: 13-18.

    , ,